Economic outcomes associated with the use of hematopoietic growth factors.
The myeloid growth factors G-CSF and GM-CSF have had an impact on the supportive care of cancer patients as well as on the strategies utilized in chemotherapy dose intensification. Therapy with these factors has not been associated with improvements in survival, and hence an examination of their effects on economic outcomes is central to rational decision making regarding their use. Erythropoietin therapy has been shown to decrease transfusion requirements in anemic cancer patients undergoing chemotherapy and to improve the quality of life in responding patients. The available data on the economic outcomes associated with the use of these three factors in oncology practice are reviewed.
Glaspy
J A
JA
Department of Medicine, UCLA School of Medicine, USA.
D003365:Costs and Cost Analysis; D016298:Hematopoietic Cell Growth Factors / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000191:economics
D016298:Hematopoietic Cell Growth Factors